AD Michelson, MR Barnard, LA Krueger, AL Frelinger, … - Methods, 2000 - Elsevier Platelet function in whole blood can be comprehensively evaluated by flow cytometry. Flow cytometry
can be used to measure platelet reactivity, circulating activated platelets, platelet–platelet
aggregates, leukocyte–platelet aggregates, procoagulant platelet-derived microparticles, ... Cited by 202 - Related articles - BL Direct - All 7 versions
- ►ahajournals.org DJ Angiolillo, SB Shoemaker, B Desai, H Yuan, RK … - Circulation, 2007 - Am Heart Assoc Methods and Results— T2DM patients on chronic dual antiplatelet therapy were screened to
identify suboptimal clopidogrel responders. The latter were randomized to 30-day treatment with
a standard (75 mg; n=20) or high (150 mg; n=20) daily maintenance dose. Platelet ... Cited by 156 - Related articles - All 8 versions
- ►onlinejacc.org DJ Angiolillo, A Fernandez-Ortiz, E Bernardo, F … - Journal of the American …, 2007 - Elsevier Antiplatelet therapy is the cornerstone of treatment for patients with acute coronary syndromes
and/or undergoing percutaneous coronary interventions. Clopidogrel, in combination with
aspirin, is currently the antiplatelet treatment of choice for prevention of stent thrombosis, ... Cited by 156 - Related articles - BL Direct - All 19 versions
- ►onlinejacc.org PA Gurbel, RC Becker, KG Mann, SR Steinhubl, AD … - Journal of the American …, 2007 - Elsevier Studies focused on patient responsiveness to antiplatelet therapies, particularly aspirin and
clopidogrel, have increased in recent years. However, the relations of in vivo platelet function
and adverse clinical events to results of ex vivo platelet function tests remain largely ... Cited by 92 - Related articles - BL Direct - All 28 versions
- ►onlinejacc.org DJ Angiolillo, E Bernardo, C Ramírez, MA Costa, M … - Journal of the American …, 2006 - Elsevier Insulin inhibits platelet aggregation by suppressing the P2Y 12 pathway. However, T2DM patients
have a loss of responsiveness to insulin that leads to upregulation of the P2Y 12 pathway, increased
platelet reactivity, and reduced responsiveness to antiplatelet agents. Patients with ... Cited by 79 - Related articles - BL Direct - All 23 versions
- ►onlinejacc.org DJ Angiolillo, E Bernardo, M Sabaté, P Jimenez- … - Journal of the American …, 2007 - Elsevier Type 2 diabetes mellitus patients have increased platelet reactivity compared with nondiabetic
patients. Whether HPR assessed in T2DM while in their steady-state phase of dual antiplatelet
therapy is associated with an increased risk of major adverse cardiovascular events ... Cited by 62 - Related articles - BL Direct - All 33 versions
- ►shouxi.net VL Serebruany, AI Malinin, A Pokov, G Barsness, DF … - American heart journal, 2007 - Elsevier There were no differences in the baseline clinical and platelet characteristics between the C
+ ASA and ASA groups, or subsequent significant changes in platelet biomarkers in the ASA
group, except for diminished collagen-induced aggregation (P = .02). In contrast, when ... Cited by 53 - Related articles - All 25 versions
DJ Angiolillo, A Fernandez-Ortiz, E Bernardo, C … - Diabetes, 2006 - Am Diabetes Assoc Inhibition of the P2Y 12 pathway by the platelet antagonist clopidogrel is associated with a marked
reduction in platelet reactivity. Recent reports have shown that P2Y 12 inhibition has anti-inflammatory
effects as well. However, whether clopidogrel withdrawal is associated with ... Cited by 52 - Related articles - BL Direct - All 6 versions
- ►mayoclinicproceedings.com … R Ardehali, RS Blumenthal, RA Lange … - Mayo Clinic …, 2006 - mayoclinicproceedings.com Despite aspirin's and clopidogrel's proven benefit in reducing cardiovascular (CV) events, recurrent
CV events still occur in patients receiving antiplatelet therapy. Many of these patients are resistant
or only partially responsive to the antiplatelet effects of aspirin and clopidogrel, as ... Cited by 51 - Related articles - BL Direct - All 9 versions
- ►theheart.org [PDF] PA Gurbel, US Tantry - Thrombosis research, 2007 - Elsevier Clopidogrel is an effective inhibitor of platelet activation and aggregation due to its selective
and irreversible blockade of the P2Y 12 receptor. Combination antiplatelet therapy with clopidogrel
and aspirin is an important strategy for patients with acute coronary syndromes and those ... Cited by 50 - Related articles - All 15 versions
